These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 12901232

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges.
    Ahmad K, Lee EJ, Shaikh S, Kumar A, Rao KM, Park SY, Jin JO, Han SS, Choi I.
    Semin Cancer Biol; 2021 Feb; 69():325-336. PubMed ID: 31454671
    [Abstract] [Full Text] [Related]

  • 44. Small Molecules for Active Targeting in Cancer.
    Kue CS, Kamkaew A, Burgess K, Kiew LV, Chung LY, Lee HB.
    Med Res Rev; 2016 May; 36(3):494-575. PubMed ID: 26992114
    [Abstract] [Full Text] [Related]

  • 45. Small molecule antagonists of integrin receptors.
    Perdih A, Dolenc MS.
    Curr Med Chem; 2010 May; 17(22):2371-92. PubMed ID: 20491638
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. New Targets and Innovative Strategies in Cancer Treatment: one year of progress. 13-14 February 2004, Nice, France.
    Swanton C, Johnston S.
    IDrugs; 2004 Apr; 7(4):306-11. PubMed ID: 15057631
    [No Abstract] [Full Text] [Related]

  • 48. Tumor-penetrating peptides: a shift from magic bullets to magic guns.
    Feron O.
    Sci Transl Med; 2010 Jun 02; 2(34):34ps26. PubMed ID: 20519716
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Intracellular targets as source for cleaner targets for the treatment of solid tumors.
    Gerber HP, Sibener LV, Lee LJ, Gee M.
    Biochem Pharmacol; 2019 Oct 02; 168():275-284. PubMed ID: 31323186
    [Abstract] [Full Text] [Related]

  • 52. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.
    Reardon DA, Cheresh D.
    Genes Cancer; 2011 Dec 02; 2(12):1159-65. PubMed ID: 22866207
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications.
    Mousa SA.
    Curr Opin Chem Biol; 2002 Aug 02; 6(4):534-41. PubMed ID: 12133730
    [Abstract] [Full Text] [Related]

  • 57. Quantitation and kinetics of CD51 surface receptor expression: implications for targeted delivery.
    Smith RA, Giorgio TD.
    Ann Biomed Eng; 2004 May 02; 32(5):635-44. PubMed ID: 15171619
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.